Clinical Research Directory
Browse clinical research sites, groups, and studies.
First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
Sponsor: First Hospital of China Medical University
Summary
Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.
Official title: Development and Evaluation of 68Ga-DOTA-EphA2: A Novel Imaging Agent Targeting EphA2 for Malignant Tumor
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2026-05-01
Completion Date
2027-12-31
Last Updated
2026-05-18
Healthy Volunteers
No
Conditions
Interventions
68Ga- DOTA-EphA2 PET/CT Imaging of Malignant Tumor
Study of the Radioligand 68Ga- DOTA-EphA2 for PET/CT Imaging of Malignant Tumor
Locations (1)
PET
Shenyang, Liaoning, China